AstraZeneca Achieves Positive Phase III Results for COPD Drug [TheStreet.com]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: TheStreet.com
Despite standard inhaled treatments, more than 50% of patients continue to experience debilitating exacerbations. AstraZeneca PLC (NYSE: AZN) aims to address this critical medical gap with its experimental drug, tozorakimab. The biotechnology leader recently reported that tozorakimab successfully met the primary endpoint in the Phase III MIRANDA trial. The treatment demonstrated a statistically significant reduction in the annualized rate of moderate-to-severe exacerbations for patients suffering from chronic obstructive pulmonary disease (COPD). This article examines the clinical efficacy of tozorakimab, its innovative mechanism of action, and AstraZeneca's strategic plans for regulatory submission. The MIRANDA Trial Demonstrates Clinical Efficacy AstraZeneca designed the MIRANDA trial to evaluate the efficacy and safety of tozorakimab in a highly specific patient population. The study enrolled individuals with COPD who continued to experience moderate-to-severe exacerbations w
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDBusiness Wire
- Astrazeneca (AZN) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
- Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]Yahoo! Finance
- IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancerBusiness Wire
- Deutsche Bank Maintains Sell on AstraZeneca (AZN) [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/20/26 - Form 6-K
- 4/9/26 - Form 6-K
- 4/8/26 - Form 25-NSE
- AZN's page on the SEC website